Use of pathology-specific peripheral blood CD34 thresholds to predict leukapheresis CD34 content with optimal accuracy: a bicentric analysis of 299 leukaphereses
CD34+ cell counts in peripheral blood (PB) and corresponding numbers of CD34+ cells and colony-forming units-granulocyte/macrophage (CFU-GM) in 299 leukapheresis products of 209 patients undergoing PB progenitor cell (PBPC) mobilization for autologous transplantation in two different centers were an...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2001-11, Vol.80 (11), p.639-646 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 646 |
|---|---|
| container_issue | 11 |
| container_start_page | 639 |
| container_title | Annals of hematology |
| container_volume | 80 |
| creator | DOBO, I ROBILLARD, N PINEAU, D GENEVIEVE, F PIARD, N RAPP, M.-J BOASSON, M ZANDECKI, M HERMOUET, S |
| description | CD34+ cell counts in peripheral blood (PB) and corresponding numbers of CD34+ cells and colony-forming units-granulocyte/macrophage (CFU-GM) in 299 leukapheresis products of 209 patients undergoing PB progenitor cell (PBPC) mobilization for autologous transplantation in two different centers were analyzed and compared according to diagnosis: non-Hodgkin lymphoma (NHL, 94 leukaphereses), multiple myeloma (MM, 75), Hodgkin's disease (HD, 37), solid tumors (35), and chronic myeloid leukemia (CML, 32). Without separating disease entities, correlations between PB CD34+ cell counts and leukapheresis content of CD34+ cells (r>0.83, P0.81, P 10(6) CD34/kg was determined. This threshold was higher in center 1 than in center 2, and its predictive accuracy (91.4%, i.e., prediction correct 91.4% of the time) was significantly lower than in center 2 (98.4%, P=0.02). When data were analyzed by pathology, PB CD34+ cell counts and leukapheresis content of CD34+ cells and CFU-GM remained well correlated, and in both centers PB CD34 thresholds predictive of a yield > 10(6) CD34/kg per leukapheresis could be determined for each pathology. For most patients, pathology-specific PB CD34 thresholds could be obtained directly from the equation of the PB CD34/leukapheresis CD34 correlation curve; they varied depending on both pathology and center (range: 7-20 x 10(6) CD34/l). Pathology-specific thresholds predicted a leukapheresis yield > or = 10(6) CD34/kg accurately 100% of the time for MM patients in center 2 and HD and solid tumor patients of both centers, resulting in overall rates of accurate prediction of sufficient graft CD34 content of 96.6% in center 1 and 98.9% in center 2. |
| doi_str_mv | 10.1007/s002770100365 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72328005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2667930051</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-e26290e821c4415cee8b8c6ad24f41264d76ed5ab6740656d99fa981fc751d9e3</originalsourceid><addsrcrecordid>eNpd0U2L1DAYB_Agiju7evQqAXFv1bw2jbdlfIUFL-65pMlTJ2unqXlSZD6O39QMM7BqLynkl39e_oS84OwNZ8y8RcaEMaz-y1Y_IhuupGiY7tRjsmFW2kbX74JcIt4zxkWnxFNywbnRxgixIb_vEGga6eLKLk3p-6HBBXwco6cL5LjsILuJDlNKgW7fS0XLLgNWGpCWRJcMIfpCJ1h_uCMGjHiCPs0F5kJ_xbKjaSlxX4Oc92t2_vCOOjpEX-dz3cnNbjocF9aDCGv_TgN8Rp6MbkJ4fh6vyN3HD9-2n5vbr5--bG9uGy-VKQ2IVlgGneBeKa49QDd0vnVBqFFx0apgWgjaDa1RrNVtsHZ0tuOjN5oHC_KKXJ9yl5x-roCl30f0ME1uhrRib4QUHWO6wlf_wfu05noF7DnjWnbKGlNVc1I-J8QMY7_k-gT5UFF_bK7_p7nqX55T12EP4UGfq6rg9Rk49G4as5t9xAenOLe1YfkHLtShMg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1015384977</pqid></control><display><type>article</type><title>Use of pathology-specific peripheral blood CD34 thresholds to predict leukapheresis CD34 content with optimal accuracy: a bicentric analysis of 299 leukaphereses</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>DOBO, I ; ROBILLARD, N ; PINEAU, D ; GENEVIEVE, F ; PIARD, N ; RAPP, M.-J ; BOASSON, M ; ZANDECKI, M ; HERMOUET, S</creator><creatorcontrib>DOBO, I ; ROBILLARD, N ; PINEAU, D ; GENEVIEVE, F ; PIARD, N ; RAPP, M.-J ; BOASSON, M ; ZANDECKI, M ; HERMOUET, S</creatorcontrib><description>CD34+ cell counts in peripheral blood (PB) and corresponding numbers of CD34+ cells and colony-forming units-granulocyte/macrophage (CFU-GM) in 299 leukapheresis products of 209 patients undergoing PB progenitor cell (PBPC) mobilization for autologous transplantation in two different centers were analyzed and compared according to diagnosis: non-Hodgkin lymphoma (NHL, 94 leukaphereses), multiple myeloma (MM, 75), Hodgkin's disease (HD, 37), solid tumors (35), and chronic myeloid leukemia (CML, 32). Without separating disease entities, correlations between PB CD34+ cell counts and leukapheresis content of CD34+ cells (r>0.83, P<0.01) and CFU-GM (r>0.81, P<0.01) were excellent. In both centers, a PB CD34 threshold ensuring a leukapheresis yield > 10(6) CD34/kg was determined. This threshold was higher in center 1 than in center 2, and its predictive accuracy (91.4%, i.e., prediction correct 91.4% of the time) was significantly lower than in center 2 (98.4%, P=0.02). When data were analyzed by pathology, PB CD34+ cell counts and leukapheresis content of CD34+ cells and CFU-GM remained well correlated, and in both centers PB CD34 thresholds predictive of a yield > 10(6) CD34/kg per leukapheresis could be determined for each pathology. For most patients, pathology-specific PB CD34 thresholds could be obtained directly from the equation of the PB CD34/leukapheresis CD34 correlation curve; they varied depending on both pathology and center (range: 7-20 x 10(6) CD34/l). Pathology-specific thresholds predicted a leukapheresis yield > or = 10(6) CD34/kg accurately 100% of the time for MM patients in center 2 and HD and solid tumor patients of both centers, resulting in overall rates of accurate prediction of sufficient graft CD34 content of 96.6% in center 1 and 98.9% in center 2.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s002770100365</identifier><identifier>PMID: 11757722</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adolescent ; Adult ; Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Antigens, CD34 - analysis ; Biological and medical sciences ; Blood Cells - chemistry ; Blood Cells - transplantation ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; Cells, Cultured ; Child ; Child, Preschool ; Colony-Forming Units Assay ; Female ; Forecasting ; Hematologic Neoplasms - blood ; Hematologic Neoplasms - pathology ; Hematologic Neoplasms - therapy ; Hematopoietic Stem Cell Transplantation - methods ; Hematopoietic Stem Cells - chemistry ; Humans ; Leukapheresis - methods ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy ; Lymphoma - blood ; Lymphoma - pathology ; Lymphoma - therapy ; Male ; Medical sciences ; Middle Aged ; Myeloid Progenitor Cells - physiology ; Neoplasms - blood ; Neoplasms - pathology ; Neoplasms - therapy ; Sensitivity and Specificity ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><ispartof>Annals of hematology, 2001-11, Vol.80 (11), p.639-646</ispartof><rights>2002 INIST-CNRS</rights><rights>Springer-Verlag 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-e26290e821c4415cee8b8c6ad24f41264d76ed5ab6740656d99fa981fc751d9e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14119001$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11757722$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DOBO, I</creatorcontrib><creatorcontrib>ROBILLARD, N</creatorcontrib><creatorcontrib>PINEAU, D</creatorcontrib><creatorcontrib>GENEVIEVE, F</creatorcontrib><creatorcontrib>PIARD, N</creatorcontrib><creatorcontrib>RAPP, M.-J</creatorcontrib><creatorcontrib>BOASSON, M</creatorcontrib><creatorcontrib>ZANDECKI, M</creatorcontrib><creatorcontrib>HERMOUET, S</creatorcontrib><title>Use of pathology-specific peripheral blood CD34 thresholds to predict leukapheresis CD34 content with optimal accuracy: a bicentric analysis of 299 leukaphereses</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><description>CD34+ cell counts in peripheral blood (PB) and corresponding numbers of CD34+ cells and colony-forming units-granulocyte/macrophage (CFU-GM) in 299 leukapheresis products of 209 patients undergoing PB progenitor cell (PBPC) mobilization for autologous transplantation in two different centers were analyzed and compared according to diagnosis: non-Hodgkin lymphoma (NHL, 94 leukaphereses), multiple myeloma (MM, 75), Hodgkin's disease (HD, 37), solid tumors (35), and chronic myeloid leukemia (CML, 32). Without separating disease entities, correlations between PB CD34+ cell counts and leukapheresis content of CD34+ cells (r>0.83, P<0.01) and CFU-GM (r>0.81, P<0.01) were excellent. In both centers, a PB CD34 threshold ensuring a leukapheresis yield > 10(6) CD34/kg was determined. This threshold was higher in center 1 than in center 2, and its predictive accuracy (91.4%, i.e., prediction correct 91.4% of the time) was significantly lower than in center 2 (98.4%, P=0.02). When data were analyzed by pathology, PB CD34+ cell counts and leukapheresis content of CD34+ cells and CFU-GM remained well correlated, and in both centers PB CD34 thresholds predictive of a yield > 10(6) CD34/kg per leukapheresis could be determined for each pathology. For most patients, pathology-specific PB CD34 thresholds could be obtained directly from the equation of the PB CD34/leukapheresis CD34 correlation curve; they varied depending on both pathology and center (range: 7-20 x 10(6) CD34/l). Pathology-specific thresholds predicted a leukapheresis yield > or = 10(6) CD34/kg accurately 100% of the time for MM patients in center 2 and HD and solid tumor patients of both centers, resulting in overall rates of accurate prediction of sufficient graft CD34 content of 96.6% in center 1 and 98.9% in center 2.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Antigens, CD34 - analysis</subject><subject>Biological and medical sciences</subject><subject>Blood Cells - chemistry</subject><subject>Blood Cells - transplantation</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>Cells, Cultured</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Colony-Forming Units Assay</subject><subject>Female</subject><subject>Forecasting</subject><subject>Hematologic Neoplasms - blood</subject><subject>Hematologic Neoplasms - pathology</subject><subject>Hematologic Neoplasms - therapy</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Hematopoietic Stem Cells - chemistry</subject><subject>Humans</subject><subject>Leukapheresis - methods</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy</subject><subject>Lymphoma - blood</subject><subject>Lymphoma - pathology</subject><subject>Lymphoma - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myeloid Progenitor Cells - physiology</subject><subject>Neoplasms - blood</subject><subject>Neoplasms - pathology</subject><subject>Neoplasms - therapy</subject><subject>Sensitivity and Specificity</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0U2L1DAYB_Agiju7evQqAXFv1bw2jbdlfIUFL-65pMlTJ2unqXlSZD6O39QMM7BqLynkl39e_oS84OwNZ8y8RcaEMaz-y1Y_IhuupGiY7tRjsmFW2kbX74JcIt4zxkWnxFNywbnRxgixIb_vEGga6eLKLk3p-6HBBXwco6cL5LjsILuJDlNKgW7fS0XLLgNWGpCWRJcMIfpCJ1h_uCMGjHiCPs0F5kJ_xbKjaSlxX4Oc92t2_vCOOjpEX-dz3cnNbjocF9aDCGv_TgN8Rp6MbkJ4fh6vyN3HD9-2n5vbr5--bG9uGy-VKQ2IVlgGneBeKa49QDd0vnVBqFFx0apgWgjaDa1RrNVtsHZ0tuOjN5oHC_KKXJ9yl5x-roCl30f0ME1uhrRib4QUHWO6wlf_wfu05noF7DnjWnbKGlNVc1I-J8QMY7_k-gT5UFF_bK7_p7nqX55T12EP4UGfq6rg9Rk49G4as5t9xAenOLe1YfkHLtShMg</recordid><startdate>20011101</startdate><enddate>20011101</enddate><creator>DOBO, I</creator><creator>ROBILLARD, N</creator><creator>PINEAU, D</creator><creator>GENEVIEVE, F</creator><creator>PIARD, N</creator><creator>RAPP, M.-J</creator><creator>BOASSON, M</creator><creator>ZANDECKI, M</creator><creator>HERMOUET, S</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20011101</creationdate><title>Use of pathology-specific peripheral blood CD34 thresholds to predict leukapheresis CD34 content with optimal accuracy: a bicentric analysis of 299 leukaphereses</title><author>DOBO, I ; ROBILLARD, N ; PINEAU, D ; GENEVIEVE, F ; PIARD, N ; RAPP, M.-J ; BOASSON, M ; ZANDECKI, M ; HERMOUET, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-e26290e821c4415cee8b8c6ad24f41264d76ed5ab6740656d99fa981fc751d9e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Antigens, CD34 - analysis</topic><topic>Biological and medical sciences</topic><topic>Blood Cells - chemistry</topic><topic>Blood Cells - transplantation</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>Cells, Cultured</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Colony-Forming Units Assay</topic><topic>Female</topic><topic>Forecasting</topic><topic>Hematologic Neoplasms - blood</topic><topic>Hematologic Neoplasms - pathology</topic><topic>Hematologic Neoplasms - therapy</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Hematopoietic Stem Cells - chemistry</topic><topic>Humans</topic><topic>Leukapheresis - methods</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy</topic><topic>Lymphoma - blood</topic><topic>Lymphoma - pathology</topic><topic>Lymphoma - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myeloid Progenitor Cells - physiology</topic><topic>Neoplasms - blood</topic><topic>Neoplasms - pathology</topic><topic>Neoplasms - therapy</topic><topic>Sensitivity and Specificity</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DOBO, I</creatorcontrib><creatorcontrib>ROBILLARD, N</creatorcontrib><creatorcontrib>PINEAU, D</creatorcontrib><creatorcontrib>GENEVIEVE, F</creatorcontrib><creatorcontrib>PIARD, N</creatorcontrib><creatorcontrib>RAPP, M.-J</creatorcontrib><creatorcontrib>BOASSON, M</creatorcontrib><creatorcontrib>ZANDECKI, M</creatorcontrib><creatorcontrib>HERMOUET, S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DOBO, I</au><au>ROBILLARD, N</au><au>PINEAU, D</au><au>GENEVIEVE, F</au><au>PIARD, N</au><au>RAPP, M.-J</au><au>BOASSON, M</au><au>ZANDECKI, M</au><au>HERMOUET, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of pathology-specific peripheral blood CD34 thresholds to predict leukapheresis CD34 content with optimal accuracy: a bicentric analysis of 299 leukaphereses</atitle><jtitle>Annals of hematology</jtitle><addtitle>Ann Hematol</addtitle><date>2001-11-01</date><risdate>2001</risdate><volume>80</volume><issue>11</issue><spage>639</spage><epage>646</epage><pages>639-646</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>CD34+ cell counts in peripheral blood (PB) and corresponding numbers of CD34+ cells and colony-forming units-granulocyte/macrophage (CFU-GM) in 299 leukapheresis products of 209 patients undergoing PB progenitor cell (PBPC) mobilization for autologous transplantation in two different centers were analyzed and compared according to diagnosis: non-Hodgkin lymphoma (NHL, 94 leukaphereses), multiple myeloma (MM, 75), Hodgkin's disease (HD, 37), solid tumors (35), and chronic myeloid leukemia (CML, 32). Without separating disease entities, correlations between PB CD34+ cell counts and leukapheresis content of CD34+ cells (r>0.83, P<0.01) and CFU-GM (r>0.81, P<0.01) were excellent. In both centers, a PB CD34 threshold ensuring a leukapheresis yield > 10(6) CD34/kg was determined. This threshold was higher in center 1 than in center 2, and its predictive accuracy (91.4%, i.e., prediction correct 91.4% of the time) was significantly lower than in center 2 (98.4%, P=0.02). When data were analyzed by pathology, PB CD34+ cell counts and leukapheresis content of CD34+ cells and CFU-GM remained well correlated, and in both centers PB CD34 thresholds predictive of a yield > 10(6) CD34/kg per leukapheresis could be determined for each pathology. For most patients, pathology-specific PB CD34 thresholds could be obtained directly from the equation of the PB CD34/leukapheresis CD34 correlation curve; they varied depending on both pathology and center (range: 7-20 x 10(6) CD34/l). Pathology-specific thresholds predicted a leukapheresis yield > or = 10(6) CD34/kg accurately 100% of the time for MM patients in center 2 and HD and solid tumor patients of both centers, resulting in overall rates of accurate prediction of sufficient graft CD34 content of 96.6% in center 1 and 98.9% in center 2.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>11757722</pmid><doi>10.1007/s002770100365</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2001-11, Vol.80 (11), p.639-646 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72328005 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adolescent Adult Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Antigens, CD34 - analysis Biological and medical sciences Blood Cells - chemistry Blood Cells - transplantation Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis Cells, Cultured Child Child, Preschool Colony-Forming Units Assay Female Forecasting Hematologic Neoplasms - blood Hematologic Neoplasms - pathology Hematologic Neoplasms - therapy Hematopoietic Stem Cell Transplantation - methods Hematopoietic Stem Cells - chemistry Humans Leukapheresis - methods Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy Lymphoma - blood Lymphoma - pathology Lymphoma - therapy Male Medical sciences Middle Aged Myeloid Progenitor Cells - physiology Neoplasms - blood Neoplasms - pathology Neoplasms - therapy Sensitivity and Specificity Transfusions. Complications. Transfusion reactions. Cell and gene therapy |
| title | Use of pathology-specific peripheral blood CD34 thresholds to predict leukapheresis CD34 content with optimal accuracy: a bicentric analysis of 299 leukaphereses |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T08%3A25%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20pathology-specific%20peripheral%20blood%20CD34%20thresholds%20to%20predict%20leukapheresis%20CD34%20content%20with%20optimal%20accuracy:%20a%20bicentric%20analysis%20of%20299%20leukaphereses&rft.jtitle=Annals%20of%20hematology&rft.au=DOBO,%20I&rft.date=2001-11-01&rft.volume=80&rft.issue=11&rft.spage=639&rft.epage=646&rft.pages=639-646&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s002770100365&rft_dat=%3Cproquest_cross%3E2667930051%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1015384977&rft_id=info:pmid/11757722&rfr_iscdi=true |